Impact of the new AJCC staging system and adjuvant treatment in rectal cancer.
OBJECTIVE
The combination of chemoradiation and fluorouracil based chemotherapy has been the standard adjuvant treatment for colorectal cancer patients. The aim of this study was to evaluate treatment outcome of patients classified by the new AJCC staging system and to compare treatment outcome of oral doxifluridine and the standard Mayo Clinic regimen after chemoradiation in advanced rectal cancer patients.


METHODS
One hundred nine patients underwent curative surgical resection and chemoradiation followed by chemotherapy. 45 Gy pelvic irradiation was given to the entire pelvis and the boost radiation with 50.4 to 54 Gy, and simultaneously 5-fluorouracil (5-FU) 375 mg/m(2)/day was given on day 1 approximately 3 and 26 approximately 28. After the completion of chemoradiation, patients were given either 6 cycles of the Mayo Clinic regimen (5-FU 425 mg/m(2) plus leucovorin 20 mg/m(2) intravenous bolus infusion on day 1~5, every 4 weeks) or oral doxifluridine (600 mg/m(2)/day) for 1 year.


RESULTS
The median follow-up duration was 30 months. Among 102 evaluable patients, 38 patients (37.3%) relapsed: the locoregional recurrence in 10 patients (9.8%) and systemic relapse in 28 patients (27.5%). The systemic relapse rate was 15.6% in the stage IIA, 25.0% in the stage IIIB , and 59.1% in the stage IIIC (p=0.048). The 5-year disease-free survival (DFS) rate was significantly higher in the IIA and IIIA patients than the IIIB and IIIC patients (72% and 100% vs 48.1% and 11.2%, respectively. p<0.001). The 5-year overall survival (OS) rate was also significantly different between in the IIA/IIIA patients and the IIIB/IIIC (67.3%/100% vs 48.4%/22.3%. p<0.001). However, the difference in DFS or OS between the oral doxifluridine group and the Mayo Clinic regimen group was not significant. Cox regression multivariate analyses showed that the new AJCC stage and tumor differentiation were significant independent prognostic factors in DFS and OS.


CONCLUSIONS
These results support that the new AJCC staging system is superior to Dukes' staging system in the prognostic stratification. Regarding DFS and OS, oral doxifluridine is comparable to the standard Mayo Clinic regimen in rectal cancer patients when combined with postoperative chemoradiation. Stage IIIC patients should be selected for aggressive therapy as they have a dismal prognosis.
Lee
Shin Ae
SA
Department of Internal Medicine, College of Medicine, Dong-A University, Busan, Korea.
Kwon
Hyuk-Chan
HC
Park
Min Ah
MA
Jung
Chang Kil
CK
Kim
Sung-Hyun
SH
Park
Ki-Jae
KJ
Choi
Hong-Jo
HJ
Lee
Hyung-Sik
HS
Roh
Mee Sook
MS
Kim
Jae-Seok
JS
Kim
Hyo-Jin
HJ
J Clin Oncol. 2004 May 15;22(10):1778-84
14769855
Cancer Res. 1983 Jun;43(6):2525-8
6221792
Ann Surg. 2002 Oct;236(4):416-21; discussion 421
12368669
J Clin Oncol. 1997 Jan;15(1):110-5
8996131
Lancet. 1995 Apr 15;345(8955):939-44
7715291
N Engl J Med. 1991 Mar 14;324(11):709-15
1997835
Jpn J Clin Oncol. 2001 Jan;31(1):25-9
11256837
J Clin Oncol. 2002 Apr 1;20(7):1744-50
11919230
Eur J Cancer (1965). 1980 Apr;16(4):427-32
6447071
J Am Coll Surg. 1995 Jun;180(6):705-12
7773484
Anticancer Drugs. 1998 Aug;9(7):599-602
9773803
J Natl Cancer Inst. 1988 Mar 2;80(1):21-9
3276900
Lancet. 2001 Oct 20;358(9290):1291-304
11684209
CA Cancer J Clin. 2001 Jan-Feb;51(1):15-36
11577478
Cancer. 2001 Dec 1;92(11):2754-9
11753948
JAMA. 1990 Sep 19;264(11):1444-50
2202842
Chem Pharm Bull (Tokyo). 1983 Jan;31(1):175-8
6221809
J Clin Oncol. 1998 Jan;16(1):301-8
9440757
N Engl J Med. 1994 Aug 25;331(8):502-7
8041415
Cancer Res Treat. 2002 Apr;34(2):77-83
26680846